Functional Immune Biomarkers, Multi-Omics and AI-Driven Precision Medicine for Chronic Diseases

PrustyLab seeks to collaborate with clinical and AI-driven research consortia developing predictive biomarkers for chronic diseases, with particular expertise in post-infectious immune dysfunction and molecular disease heterogeneity.

Our group combines molecular virology, immunology, mitochondrial biology and systems-level approaches to investigate complex disease mechanisms. We have developed innovative experimental strategies involving patient-derived immune cells, extracellular ATP-induced functional immune responses, single-cell RNA sequencing, dynamic transcriptional profiling and molecular signatures of immune–metabolic dysfunction.

Our research in ME/CFS, Long COVID and related chronic conditions provides a foundation for exploring how functional cellular responses and molecular signatures may reveal biological disease subgroups not distinguishable through conventional clinical assessments.

We contribute innovative candidate biomarker platforms, including:

• Ex vivo immune-cell stimulation assays to reveal disease-associated functional abnormalities.

• scRNA-seq and scSLAM-seq for cellular heterogeneity and transcriptional dynamics.

• Immune–metabolic and mitochondrial functional profiling.

• Proteomics and immune–matrix interaction analyses.

• Multi-omics data generation and experimental validation of AI-prioritised candidate biomarkers.

Partners sought

We seek:

• Clinical consortia with established, deeply phenotyped longitudinal chronic disease cohorts.

• Clinical centres specialising in ME/CFS, Long COVID and related chronic immune disorders.

• AI and machine-learning groups experienced in multimodal data integration, predictive modelling and explainable AI.

• Biostatisticians, digital health specialists and clinical data infrastructure providers.

• Diagnostic biotechnology companies and SMEs developing biomarker-based personalised medicine solutions.

• Clinical trial networks capable of evaluating disease progression and treatment response.

Proposed consortium role

We are interested in leading functional biomarker discovery, mechanistic validation and immune-cell phenotyping work packages, while contributing biological interpretation and experimental validation to AI-driven predictive models.

Our ambition is to combine innovative molecular and functional disease signatures with longitudinal clinical data to advance predictive, biologically informed precision medicine.